|Bid||29.13 x 2200|
|Ask||29.19 x 1800|
|Day's range||29.07 - 29.60|
|52-week range||28.30 - 54.93|
|Beta (5Y monthly)||0.56|
|PE ratio (TTM)||15.90|
|Earnings date||29 Jan 2024 - 02 Feb 2024|
|Forward dividend & yield||1.64 (5.64%)|
|Ex-dividend date||09 Nov 2023|
|1y target est||40.00|
Texas Attorney General Ken Paxton unveils a fact-free lawsuit questioning Pfizer's COVID vaccine, which has helped to save millions of people from hospitalization and death.
Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.
– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the potential of vepdegestrant in combination with palbociclib (IBRANCE®) – – Tolerability generally consistent with the profile of palbociclib and what has been observed in other clinical trials of vepdegestrant– – Pending additional data and agreement with regulatory authorities, Arvinas and Pfizer pla